{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:05Z","timestamp":1792036865883,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04248-1","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:24:54Z","timestamp":1745940294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic Janus kinase inhibitors in the management of granuloma annulare"],"prefix":"10.1007","volume":"317","author":[{"given":"Scott","family":"Stratman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkar","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Jayne","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"George-Washburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Shokrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Guttman","family":"Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"7","key":"4248_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamadermatol.2021.1847","volume":"1","author":"JS Barbieri","year":"2021","unstructured":"Barbieri JS, Rodriguez O, Rosenbach M, Margolis D (2021) Incidence and prevalence of granuloma annulare in the united States. JAMA Dermatol Jul 1(7):824\u2013830. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1847","journal-title":"JAMA Dermatol Jul"},{"issue":"3","key":"4248_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0190-9622(80)80181-2","volume":"3","author":"JE Muhlbauer","year":"1980","unstructured":"Muhlbauer JE (1980) Granuloma annulare. J Am Acad Dermatol Sep 3(3):217\u2013230. https:\/\/doi.org\/10.1016\/s0190-9622(80)80181-2","journal-title":"J Am Acad Dermatol Sep"},{"issue":"8","key":"4248_CR3","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1111\/ijd.15832","volume":"61","author":"AC Leasure","year":"2022","unstructured":"Leasure AC, Damsky W, Cohen JM (2022) Prevalence of granuloma annulare in the united States: a cross-sectional study in the all of Us research program. Int J Dermatol Aug 61(8):e301\u2013e302. https:\/\/doi.org\/10.1111\/ijd.15832","journal-title":"Int J Dermatol Aug"},{"issue":"8","key":"4248_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jdv.12976","volume":"29","author":"J Lukacs","year":"2015","unstructured":"Lukacs J, Schliemann S, Elsner P (2015) Treatment of generalized granuloma annulare - a systematic review. J Eur Acad Dermatol Venereol Aug 29(8):1467\u20131480. https:\/\/doi.org\/10.1111\/jdv.12976","journal-title":"J Eur Acad Dermatol Venereol Aug"},{"issue":"4","key":"4248_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40257-013-0029-5","volume":"14","author":"LA Thornsberry","year":"2013","unstructured":"Thornsberry LA, English JC 3 (2013) Etiology, diagnosis, and therapeutic management of granuloma annulare: an update. Am J Clin Dermatol Aug 14(4):279\u2013290. https:\/\/doi.org\/10.1007\/s40257-013-0029-5","journal-title":"Am J Clin Dermatol Aug"},{"issue":"4","key":"4248_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000507247","volume":"236","author":"TM Nordmann","year":"2020","unstructured":"Nordmann TM, Kim JR, Dummer R, Anzengruber FA, Monocentric (2020) Retrospective analysis of 61 patients with generalized granuloma annulare. Dermatology 236(4):369\u2013374. https:\/\/doi.org\/10.1159\/000507247","journal-title":"Dermatology"},{"issue":"2","key":"4248_CR7","first-page":"102","volume":"103","author":"CB Rubin","year":"2019","unstructured":"Rubin CB, Rosenbach M (2019) Granuloma annulare: a retrospective series of 133 patients. Cutis Feb 103(2):102\u2013106","journal-title":"Cutis Feb"},{"key":"4248_CR8","doi-asserted-by":"crossref","unstructured":"Chandan N, Boen M, Lake EP, Aronson I (2018) Successful treatment of two individual cases of generalized granuloma annulare with amoxicillin\/clavulanic acid and a combination of Doxycycline and Pentoxifylline. Dermatol Online J Aug 15;24(8)","DOI":"10.5070\/D3248041159"},{"issue":"2","key":"4248_CR9","doi-asserted-by":"publisher","first-page":"e14864","DOI":"10.1111\/dth.14864","volume":"34","author":"E Eid","year":"2021","unstructured":"Eid E, Zein-El-Dine S, Kurban M, Abbas O (2021) Generalized granuloma annulare associated with interstitial lung disease: good response to Doxycycline. Dermatol Ther Mar 34(2):e14864. https:\/\/doi.org\/10.1111\/dth.14864","journal-title":"Dermatol Ther Mar"},{"issue":"2","key":"4248_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1080\/09546634.2020.1801973","volume":"33","author":"N Mostafa","year":"2022","unstructured":"Mostafa N, Phan K, Smith SD (2022) Antimalarial therapy for granuloma annulare: a systematic review. J Dermatolog Treat Mar 33(2):1202\u20131203. https:\/\/doi.org\/10.1080\/09546634.2020.1801973","journal-title":"J Dermatolog Treat Mar"},{"issue":"11","key":"4248_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamadermatol.2019.2130","volume":"1","author":"A Bishnoi","year":"2019","unstructured":"Bishnoi A, Raj D, Vinay K, Dogra S (2019) Refractory generalized granuloma annulare treated with oral Apremilast. JAMA Dermatol Nov 1(11):1318\u20131320. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2130","journal-title":"JAMA Dermatol Nov"},{"issue":"1","key":"4248_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2021.07.037","volume":"87","author":"ML Hrin","year":"2022","unstructured":"Hrin ML, Bowers NL, Feldman SR, Huang WW (2022) Methotrexate for generalized granuloma annulare: A 60% response rate in a retrospective case series of 15 patients. J Am Acad Dermatol Jul 87(1):201\u2013203. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.037","journal-title":"J Am Acad Dermatol Jul"},{"issue":"7","key":"4248_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/09546634.2018.1447075","volume":"29","author":"F Naka","year":"2018","unstructured":"Naka F, Strober BE (2018) Methotrexate treatment of generalized granuloma annulare: a retrospective case series. J Dermatolog Treat Nov 29(7):720\u2013724. https:\/\/doi.org\/10.1080\/09546634.2018.1447075","journal-title":"J Dermatolog Treat Nov"},{"issue":"9","key":"4248_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1346-8138.14981","volume":"46","author":"C Burgler","year":"2019","unstructured":"Burgler C, Vinay K, Hafliger S, Klotgen HW, Yawalkar N (2019) Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3-positive cells in granuloma annulare. J Dermatol Sep 46(9):808\u2013811. https:\/\/doi.org\/10.1111\/1346-8138.14981","journal-title":"J Dermatol Sep"},{"issue":"9","key":"4248_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jdcr.2020.07.013","volume":"6","author":"M Fassler","year":"2020","unstructured":"Fassler M, Schlapbach C (2020) Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab. JAAD Case Rep Sep 6(9):832\u2013834. https:\/\/doi.org\/10.1016\/j.jdcr.2020.07.013","journal-title":"JAAD Case Rep Sep"},{"issue":"1","key":"4248_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jaad.2015.09.015","volume":"74","author":"MS Min","year":"2016","unstructured":"Min MS, Lebwohl M (2016) Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. J Am Acad Dermatol Jan 74(1):127\u2013133. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.015","journal-title":"J Am Acad Dermatol Jan"},{"key":"4248_CR17","unstructured":"Wang A, Singh K, Ibrahim W, King B, Damsky W (2020) The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature. Yale J Biol Med 93(1):187\u2013195"},{"issue":"1","key":"4248_CR18","doi-asserted-by":"publisher","first-page":"2313090","DOI":"10.1080\/09546634.2024.2313090","volume":"35","author":"W Liu","year":"2024","unstructured":"Liu W, Chen W, Tian X, Yu Y, Zhu J, Liang J et al (2024) Oral abrocitinib in the treatment of granuloma annulare: a case report. J Dermatolog Treat Dec 35(1):2313090. https:\/\/doi.org\/10.1080\/09546634.2024.2313090","journal-title":"J Dermatolog Treat Dec"},{"key":"4248_CR19","doi-asserted-by":"publisher","unstructured":"Michels A, Heiland R, Hammerschmidt S, Farcas A, Voigt TP, Braun SA et al (2024) Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib. J Dtsch Dermatol Ges Mar 15. https:\/\/doi.org\/10.1111\/ddg.15426","DOI":"10.1111\/ddg.15426"},{"issue":"3","key":"4248_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajd.13875","volume":"63","author":"X Bosch-Amate","year":"2022","unstructured":"Bosch-Amate X, Serra-Garcia L, Alamon-Reig F, Marti-Marti I, Gil-Lianes J, Giavedoni P et al (2022) Treatment of granuloma annulare with Tofacitinib. Australas J Dermatol Aug 63(3):400\u2013403. https:\/\/doi.org\/10.1111\/ajd.13875","journal-title":"Australas J Dermatol Aug"},{"issue":"1","key":"4248_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdcr.2019.10.016","volume":"6","author":"W Damsky","year":"2020","unstructured":"Damsky W, King BA (2020) Treatment of granuloma annulare with Tofacitinib 2% ointment. JAAD Case Rep Jan 6(1):69\u201371. https:\/\/doi.org\/10.1016\/j.jdcr.2019.10.016","journal-title":"JAAD Case Rep Jan"},{"issue":"3","key":"4248_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","volume":"82","author":"W Damsky","year":"2020","unstructured":"Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B (2020) Janus kinase Inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol Mar 82(3):612\u2013621. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.098","journal-title":"J Am Acad Dermatol Mar"},{"key":"4248_CR23","doi-asserted-by":"publisher","first-page":"2050313X2110394","DOI":"10.1177\/2050313X211039477","volume":"9","author":"ML McPhie","year":"2021","unstructured":"McPhie ML, Swales WC, Gooderham MJ (2021) Improvement of granulomatous skin conditions with Tofacitinib in three patients: A case report. SAGE Open Med Case Rep 9:2050313X211039477. https:\/\/doi.org\/10.1177\/2050313X211039477","journal-title":"SAGE Open Med Case Rep"},{"issue":"5","key":"4248_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jaci.2020.10.012","volume":"147","author":"A Wang","year":"2021","unstructured":"Wang A, Rahman NT, McGeary MK, Murphy M, McHenry A, Peterson D et al (2021) Treatment of granuloma annulare and suppression of Proinflammatory cytokine activity with Tofacitinib. J Allergy Clin Immunol May 147(5):1795\u20131809. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.012","journal-title":"J Allergy Clin Immunol May"},{"issue":"10","key":"4248_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jdcr.2020.07.054","volume":"6","author":"JS Durgin","year":"2020","unstructured":"Durgin JS, Shields BE, Rosenbach M (2020) Generalized granuloma annulare: A widespread response to limited application of compounded 2% topical Tofacitinib. JAAD Case Rep Oct 6(10):1113\u20131115. https:\/\/doi.org\/10.1016\/j.jdcr.2020.07.054","journal-title":"JAAD Case Rep Oct"},{"key":"4248_CR26","doi-asserted-by":"publisher","unstructured":"Jadoul A, Huygen L, Leemans G, Grosber M, Kortekaas Krohn I, Gutermuth J (2023) JAK1\/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib. J Eur Acad Dermatol Venereol Mar 28. https:\/\/doi.org\/10.1111\/jdv.19073","DOI":"10.1111\/jdv.19073"},{"issue":"4","key":"4248_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ced\/llac110","volume":"22","author":"D Kim","year":"2023","unstructured":"Kim D, Kang HY (2023) Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients. Clin Exp Dermatol Mar 22(4):375\u2013376. https:\/\/doi.org\/10.1093\/ced\/llac110","journal-title":"Clin Exp Dermatol Mar"},{"issue":"7","key":"4248_CR28","doi-asserted-by":"publisher","first-page":"e500","DOI":"10.1111\/jdv.18031","volume":"36","author":"TM Yan","year":"2022","unstructured":"Yan TM, Zhang H, Wu XY, Zhang ZY (2022) Successful treatment of generalized granuloma annulare with baricitinib. J Eur Acad Dermatol Venereol Jul 36(7):e500\u2013e502. https:\/\/doi.org\/10.1111\/jdv.18031","journal-title":"J Eur Acad Dermatol Venereol Jul"},{"issue":"8","key":"4248_CR29","doi-asserted-by":"publisher","first-page":"e15641","DOI":"10.1111\/dth.15641","volume":"35","author":"A Ballova","year":"2022","unstructured":"Ballova A, Kmecova Z, Pec J, Vorcakova K (2022) Recalcitrant granuloma annulare induced by two different biologic agents resolved after Janus kinase inhibitor treatment. Dermatol Ther Aug 35(8):e15641. https:\/\/doi.org\/10.1111\/dth.15641","journal-title":"Dermatol Ther Aug"},{"issue":"3","key":"4248_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s13555-024-01117-z","volume":"14","author":"A De Greef","year":"2024","unstructured":"De Greef A, Benjelloun G, Harkemanne E, Baeck M (2024) Successful treatment of disseminated granuloma annulare with Upadacitinib. Dermatol Ther (Heidelb) Mar 14(3):813\u2013817. https:\/\/doi.org\/10.1007\/s13555-024-01117-z","journal-title":"Dermatol Ther (Heidelb) Mar"},{"key":"4248_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jdcr.2023.11.024","volume":"44","author":"J Zheng","year":"2024","unstructured":"Zheng J, Sharma S, Wassell K, Lanzini R, Lima H (2024) Letter to the editor: effective treatment of disseminated granuloma annulare with Upadacitinib. JAAD Case Rep Feb 44:98\u2013100. https:\/\/doi.org\/10.1016\/j.jdcr.2023.11.024","journal-title":"JAAD Case Rep Feb"},{"key":"4248_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2023.01.027","volume":"34","author":"KN Slater","year":"2023","unstructured":"Slater KN, Valk B, Kartono F (2023) A case of generalized granuloma annulare treated with Upadacitinib. JAAD Case Rep Apr 34:12\u201314. https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.027","journal-title":"JAAD Case Rep Apr"},{"key":"4248_CR33","doi-asserted-by":"publisher","first-page":"8859178","DOI":"10.1155\/2024\/8859178","volume":"2024","author":"A Coican","year":"2024","unstructured":"Coican A, Meckley A, Sagasser N, Greenfield M, Song EJ, El-Bahri J (2024) Successful treatment of refractory generalized granuloma annulare with Upadacitinib. Case Rep Dermatol Med 2024:8859178. https:\/\/doi.org\/10.1155\/2024\/8859178","journal-title":"Case Rep Dermatol Med"},{"key":"4248_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdcr.2024.05.030","volume":"50","author":"AJ Piontkowski","year":"2024","unstructured":"Piontkowski AJ, Wei N, Mumtaz A, Gulati N (2024) Ruxolitinib cream for the treatment of granuloma annulare. JAAD Case Rep Aug 50:62\u201364. https:\/\/doi.org\/10.1016\/j.jdcr.2024.05.030","journal-title":"JAAD Case Rep Aug"},{"issue":"1","key":"4248_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaad.2019.12.028","volume":"83","author":"MS Min","year":"2020","unstructured":"Min MS, Wu J, He H, Sanz-Cabanillas JL, Del Duca E, Zhang N et al (2020) Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. J Am Acad Dermatol Jul 83(1):63\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.028","journal-title":"J Am Acad Dermatol Jul"},{"issue":"5","key":"4248_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/ijd.14350","volume":"58","author":"A Chen","year":"2019","unstructured":"Chen A, Truong AK, Worswick S (2019) The role of biologics in the treatment of chronic granuloma annulare. Int J Dermatol May 58(5):622\u2013626. https:\/\/doi.org\/10.1111\/ijd.14350","journal-title":"Int J Dermatol May"},{"issue":"6","key":"4248_CR37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4103\/0019-5154.91847","volume":"56","author":"M Ratnarathorn","year":"2011","unstructured":"Ratnarathorn M, Raychaudhuri SP, Naguwa S (2011) Disseminated granuloma annulare: a cutaneous adverse effect of anti-tnf agents. Indian J Dermatol Nov 56(6):752\u2013754. https:\/\/doi.org\/10.4103\/0019-5154.91847","journal-title":"Indian J Dermatol Nov"},{"issue":"4","key":"4248_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","volume":"67","author":"PV Voulgari","year":"2008","unstructured":"Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA (2008) Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis Apr 67(4):567\u2013570. https:\/\/doi.org\/10.1136\/ard.2007.075663","journal-title":"Ann Rheum Dis Apr"},{"issue":"1","key":"4248_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-020-00566-4","volume":"22","author":"N Shah","year":"2021","unstructured":"Shah N, Shah M, Drucker AM, Shear NH, Ziv M, Dodiuk-Gad RP (2021) Granulomatous cutaneous drug eruptions: A systematic review. Am J Clin Dermatol Jan 22(1):39\u201353. https:\/\/doi.org\/10.1007\/s40257-020-00566-4","journal-title":"Am J Clin Dermatol Jan"},{"key":"4248_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jdcr.2023.07.018","volume":"39","author":"C Paganini","year":"2023","unstructured":"Paganini C, Talamonti M, Campione E, Bianchi L, Galluzzo M (2023) Letter in response to the case report: recalcitrant generalized granuloma annulare treated successfully with dupilumab. JAAD Case Rep Sep 39:152\u2013154. https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.018","journal-title":"JAAD Case Rep Sep"},{"key":"4248_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2020.10.021","volume":"7","author":"EJ Song","year":"2021","unstructured":"Song EJ, Bezecny J, Farrer S (2021) Recalcitrant generalized granuloma annulare treated successfully with dupilumab. JAAD Case Rep Jan 7:1\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2020.10.021","journal-title":"JAAD Case Rep Jan"},{"issue":"7","key":"4248_CR42","doi-asserted-by":"publisher","first-page":"e27439","DOI":"10.7759\/cureus.27439","volume":"14","author":"K Phelps-Polirer","year":"2022","unstructured":"Phelps-Polirer K, Alkhatib BL, Davis C (2022) Generalized granuloma annulare associated with dupilumab therapy. Cureus Jul 14(7):e27439. https:\/\/doi.org\/10.7759\/cureus.27439","journal-title":"Cureus Jul"},{"key":"4248_CR43","unstructured":"Janus Kinase Inhibition in Granuloma Annulare. Accessed September (2024) 12th. https:\/\/clinicaltrials.gov\/study\/NCT05650736?cond=granuloma annulare26rank=1"},{"issue":"3","key":"4248_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG (2023) A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb) Mar 13(3):729\u2013749. https:\/\/doi.org\/10.1007\/s13555-023-00892-5","journal-title":"Dermatol Ther (Heidelb) Mar"},{"issue":"11","key":"4248_CR45","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","volume":"1","author":"TL Chen","year":"2022","unstructured":"Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC (2022) Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: A systematic review and Meta-analysis. JAMA Dermatol Nov 1(11):1254\u20131261. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3516","journal-title":"JAMA Dermatol Nov"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04248-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04248-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04248-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:24:58Z","timestamp":1745940298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04248-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4248"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04248-1","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reviewed and approved by Mount Sinai School of Medicine Institutional Review Board; STUDY-24-01072.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was approved by the Mount Sinai School of Medicine Institutional Review Board for a waiver of informed consent based on study protocol. The patients in this manuscript have given written informed consent to publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors Stratman, Amara, Tan, George-Washburn, Shokrian, and Lau have no conflicts to disclose. Author Khattri has received research funds on behalf of Mount Sinai from: BMS, Incyte, Takeda, Astrazeneca and is a speaker for Lilly, UCB, Abbvie, Janssen, Regeneron, and Arcutis. Author Lebwohl has received research funds on behalf of Mount Sinai from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc., and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Author Guttman-Yassky is an employee of Mount Sinai and has received research grants (paid to the institution) from Boehringer Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen. Author Guttman-Yassky is a consultant for Abbvie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., AstraZeneca, Bristol Meyers Squibb, Boerhinger-Ingelhiem, Cara Therapeutics, Centrexion Therapeutics Corporation, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, Forest Laboratories Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Horizon Therapeutics U.S.A., Inc., Incyte, Inmagene, Janssen Biotech, JT Central Pharmaceutical Research Institute, Jasper Therapeutics, Kyowa Kirin, Leo Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, NUMAB Therapeutics AG, OrbiMed AdvisorsLLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, RAPT, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., Sanofi, SATO, Schr\u00f6dinger, Inc., Sun Pharma Advanced Research Company (SPARC), Teva Branded Pharmaceutical Products R&D, UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"743"}}